Diabetes approval for Ozempic
The CHMP has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ozempic (semaglutide), from Novo Nordisk, intended for the treatment of type 2 diabetes. Ozempic will be available as a 1.34 mg/ml solution for injection. The active substance of Ozempic is semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist (ATC code: A10B). Like native GLP-1, semaglutide leads to an increase in glucose-dependent insulin secretion and a reduction in glucagon release.
The benefits with Ozempic are its clinically relevant effect on glycaemic control in patients with type 2 diabetes when used in combination with other glucose-lowering medicinal products or on its own when metformin cannot be used. Ozempic has also a beneficial effect on body weight. The most common side effects are hypoglycaemia when used in certain combinations and gastrointestinal side effects such as nausea and diarrhoea.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.